

Joel F Farley

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4883455/publications.pdf>

Version: 2024-02-01

23
papers

311
citations

1163117

8
h-index

839539

18
g-index

23
all docs

23
docs citations

23
times ranked

483
citing authors

#	ARTICLE	IF	CITATIONS
1	Primary Care Physicians™, Psychiatrists™, and Oncologists™ Coordination While Prescribing Medications for Patients With Multiple Chronic Conditions. <i>Journal of Patient Safety</i> , 2021, Publish Ahead of Print, e424-e430.	1.7	0
2	Comparing the use of individual and composite terms to evaluate adverse drug event disproportionality: a focus on glucagon-like peptide-1 receptor agonists and diabetic retinopathy. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 475-480.	2.4	6
3	Changes in chronic disease medication adherence following oral anticancer agent initiation in patients with multiple myeloma. <i>Journal of Clinical Oncology</i> , 2021, 39, e18760-e18760.	1.6	0
4	Duration of medical home participation and quality of care for patients with chronic conditions. <i>Health Services Research</i> , 2021, 56 Suppl 1, 1069-1079.	2.0	3
5	Characterizing the reach of comprehensive medication management in a population health primary care model. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2021, 4, 1410-1419.	1.0	2
6	Adaptations made to delivery of comprehensive medication management in the community pharmacy setting during COVID-19. <i>Exploratory Research in Clinical and Social Pharmacy</i> , 2021, 4, 100089.	1.0	3
7	The Association Between Medicare Low-Income Subsidy and Anticancer Treatment Uptake in Advanced Lung Cancer. <i>Journal of the National Cancer Institute</i> , 2020, 112, 637-646.	6.3	9
8	How comfortable are primary care physicians and oncologists prescribing medications for comorbidities in patients with cancer?. <i>Research in Social and Administrative Pharmacy</i> , 2020, 16, 1087-1094.	3.0	7
9	Do comprehensive medication review completion rates predict medication use and management quality?. <i>Research in Social and Administrative Pharmacy</i> , 2019, 15, 417-424.	3.0	5
10	Measuring Adherence: A Proof of Concept Study for Multiple Medications for Chronic Conditions in Alternative Payment Models. <i>Pharmacy (Basel, Switzerland)</i> , 2019, 7, 81.	1.6	6
11	Accuracy of Prescription Claims Data in Identifying Truly Nonadherent Patients. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2019, 25, 1349-1356.	0.9	5
12	Continuity of medication management among adults with schizophrenia and comorbid cardiometabolic conditions. <i>Journal of Pharmaceutical Health Services Research</i> , 2018, 9, 13-20.	0.6	6
13	Testing the organizational theory of innovation implementation effectiveness in a community pharmacy medication management program: a hurdle regression analysis. <i>Implementation Science</i> , 2018, 13, 105.	6.9	23
14	Do Medical Homes Improve Quality of Care for Persons with Multiple Chronic Conditions?. <i>Health Services Research</i> , 2018, 53, 4667-4681.	2.0	15
15	Physicians™ comfort levels with prescriptions for cancer comorbidities that they and other healthcare providers write. <i>Journal of Clinical Oncology</i> , 2018, 36, e18523-e18523.	1.6	1
16	Continuity of medication management and continuity of care: Conceptual and operational considerations. <i>SAGE Open Medicine</i> , 2014, 2, 205031211455926.	1.8	8
17	Trends and determinants of prescription medication use for treatment of osteoporosis. <i>American Journal of Health-System Pharmacy</i> , 2009, 66, 1191-1201.	1.0	19
18	Retrospective assessment of Medicaid step-therapy prior authorization policy for atypical antipsychotic medications. <i>Clinical Therapeutics</i> , 2008, 30, 1524-1539.	2.5	30

#	ARTICLE	IF	CITATIONS
19	Professional implications of the expansion of pharmacy-based medical clinics. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2007, 47, 410-415.	1.5	3
20	Racial variations in antiresorptive medication use: results from the 2000 Medical Expenditure Panel Survey (MEPS). <i>Osteoporosis International</i> , 2006, 17, 395-404.	3.1	23
21	Promotion and Market Share in the Proton Pump Inhibitor Market: A Case Study. <i>Journal of Pharmaceutical Marketing and Management</i> , 2006, 17, 39-59.	0.1	0
22	A comparison of comorbidity measurements to predict healthcare expenditures. <i>American Journal of Managed Care</i> , 2006, 12, 110-9.	1.1	133
23	Resorptive drug use among community-dwelling women in Minnesota. <i>American Journal of Health-System Pharmacy</i> , 2004, 61, 1577-1585.	1.0	4